Details for New Drug Application (NDA): 209026
✉ Email this page to a colleague
The generic ingredient in POTASSIUM CHLORIDE is calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate. There are two hundred and eighty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate profile page.
Summary for 209026
Tradename: | POTASSIUM CHLORIDE |
Applicant: | Prinston Inc |
Ingredient: | potassium chloride |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Pharmacology for NDA: 209026
Mechanism of Action | Osmotic Activity |
Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
Suppliers and Packaging for NDA: 209026
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
POTASSIUM CHLORIDE | potassium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 209026 | ANDA | Solco Healthcare LLC | 43547-552 | 43547-552-10 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (43547-552-10) |
POTASSIUM CHLORIDE | potassium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 209026 | ANDA | Solco Healthcare LLC | 43547-553 | 43547-553-10 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (43547-553-10) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 8MEQ | ||||
Approval Date: | Jun 11, 2019 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 10MEQ | ||||
Approval Date: | Jun 11, 2019 | TE: | AB | RLD: | No |
Complete Access Available with Subscription